A Predictive Model for Kidney Failure After Nephrectomy for Localized Kidney Cancer: The Kidney Cancer Risk Equation.


Journal

American journal of kidney diseases : the official journal of the National Kidney Foundation
ISSN: 1523-6838
Titre abrégé: Am J Kidney Dis
Pays: United States
ID NLM: 8110075

Informations de publication

Date de publication:
12 2023
Historique:
received: 19 12 2022
accepted: 12 06 2023
medline: 27 11 2023
pubmed: 3 7 2023
entrez: 2 7 2023
Statut: ppublish

Résumé

Nephrectomy is the mainstay of treatment for individuals with localized kidney cancer. However, surgery can potentially result in the loss of kidney function or in kidney failure requiring dialysis/kidney transplantation. There are currently no clinical tools available to preoperatively identify which patients are at risk of kidney failure over the long term. Our study developed and validated a prediction equation for kidney failure after nephrectomy for localized kidney cancer. Population-level cohort study. Adults (n=1,026) from Manitoba, Canada, with non-metastatic kidney cancer diagnosed between January 1, 2004, and December 31, 2016, who were treated with either a partial or radical nephrectomy and had at least 1 estimated glomerular filtration rate (eGFR) measurement before and after nephrectomy. A validation cohort included individuals in Ontario (n=12,043) with a diagnosis of localized kidney cancer between October 1, 2008, and September 30, 2018, who received a partial or radical nephrectomy and had at least 1 eGFR measurement before and after surgery. Age, sex, eGFR, urinary albumin-creatinine ratio, history of diabetes mellitus, and nephrectomy type (partial/radical). The primary outcome was a composite of dialysis, transplantation, or an eGFR<15mL/min/1.73m Cox proportional hazards regression models evaluated for accuracy using area under the receiver operating characteristic curve (AUC), Brier scores, calibration plots, and continuous net reclassification improvement. We also implemented decision curve analysis. Models developed in the Manitoba cohort were validated in the Ontario cohort. In the development cohort, 10.3% reached kidney failure after nephrectomy. The final model resulted in a 5-year area under the curve of 0.85 (95% CI, 0.78-0.92) in the development cohort and 0.86 (95% CI, 0.84-0.88) in the validation cohort. Further external validation needed in diverse cohorts. Our externally validated model can be easily applied in clinical practice to inform preoperative discussions about kidney failure risk in patients facing surgical options for localized kidney cancer. Patients with localized kidney cancer often experience a lot of worry about whether their kidney function will remain stable or will decline if they choose to undergo surgery for treatment. To help patients make an informed treatment decision, we developed a simple equation that incorporates 6 easily accessible pieces of patient information to predict the risk of reaching kidney failure 5 years after kidney cancer surgery. We expect that this tool has the potential to inform patient-centered discussions tailored around individualized risk, helping ensure that patients receive the most appropriate risk-based care.

Identifiants

pubmed: 37394174
pii: S0272-6386(23)00695-9
doi: 10.1053/j.ajkd.2023.06.002
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

656-665

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Auteurs

Oksana Harasemiw (O)

Chronic Disease Innovation Centre, Seven Oaks General Hospital, University of Manitoba, Winnipeg, Manitoba; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba.

Jasmir G Nayak (JG)

Men's Health Clinic Manitoba, University of Manitoba, Winnipeg, Manitoba; Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, Manitoba.

Nicholas Grubic (N)

ICES, Toronto, Ontario; Research Institute, Ottawa Hospital, Ottawa, Ontario, Canada.

Thomas W Ferguson (TW)

Chronic Disease Innovation Centre, Seven Oaks General Hospital, University of Manitoba, Winnipeg, Manitoba; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba.

Manish M Sood (MM)

ICES, Toronto, Ontario; Division of Nephrology, Department of Medicine, Ottawa Hospital, Ottawa, Ontario, Canada; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Navdeep Tangri (N)

Chronic Disease Innovation Centre, Seven Oaks General Hospital, University of Manitoba, Winnipeg, Manitoba; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba. Electronic address: ntangri@sogh.mb.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH